Published in Prostate on November 01, 1997
Evaluation of web-based, self-administered, graphical food frequency questionnaire. J Acad Nutr Diet (2014) 1.00
The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol (2012) 0.98
Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol (1999) 0.91
Serum ferritin levels and transferrin saturation in men with prostate cancer. J Natl Med Assoc (2004) 0.91
Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells. J Biol Chem (2008) 0.80
The potential for prostate cancer chemoprevention. Rev Urol (2002) 0.77
Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention. Rev Urol (2002) 0.77
Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol (2016) 0.75
Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002. Rev Urol (2003) 0.75
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen level. Br J Cancer (1999) 0.75
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors. Cancer (1969) 3.29
Relative risk trees for censored survival data. Biometrics (1992) 2.98
Exploitation of gene(s) involved in 2,4-diacetylphloroglucinol biosynthesis to confer a new biocontrol capability to a Pseudomonas strain. Appl Environ Microbiol (1992) 2.78
ISOLATION OF INFLUENZA A BY INTRAALLANTOIC INOCULATION OF UNTREATED THROAT WASHINGS. Science (1943) 2.68
Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst (1989) 2.31
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Doctors as managers. N Z Med J (2000) 2.03
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol (1996) 1.57
Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study. Clin Infect Dis (1993) 1.48
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med (1988) 1.46
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Localized primary extranodal Hodgkin's disease. Ann Intern Med (1973) 1.43
Understanding neural networks using regression trees: an application to multiple myeloma survival data. Stat Med (2001) 1.41
Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood (1991) 1.40
Maximum tolerated dose for low-dose continuous infusion cisplatin. Int J Radiat Oncol Biol Phys (1991) 1.39
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1990) 1.39
Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest (1991) 1.39
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer (1971) 1.37
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35
Coronary artery bypass grafting in an achondroplastic dwarf. Tex Heart Inst J (1995) 1.32
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. Ann Intern Med (1973) 1.27
Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg (2001) 1.25
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia (2008) 1.25
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
Transplantation system for determining the clonogenic survival of parenchymal hepatocytes exposed to ionizing radiation. Cancer Res (1981) 1.22
Activation of complement by a monoclonal cryoglobulin associated with cold urticaria. J Lab Clin Med (1969) 1.20
Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol (2000) 1.20
Failure of cytarabine in varicella-zoster infections. JAMA (1973) 1.17
Pagophagia and iron lack. JAMA (1969) 1.16
Recognition and successful management in pulmonary aspergillosis in leukemia. Cancer (1978) 1.13
Pomp combination chemotherapy of adult acute leukemia. Cancer (1973) 1.13
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol (1993) 1.12
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia (2012) 1.11
Survival in renal vascular disease. J Am Soc Nephrol (1998) 1.11
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1991) 1.10
Adaptive regression splines in the Cox model. Biometrics (1999) 1.09
Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials (1995) 1.08
Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med (1994) 1.07
A general class of nonparametric tests for survival analysis. Biometrics (1989) 1.07
Experience with emetine hydrochloride (NSC 33669) as an antitumor agent. Cancer (1971) 1.05
Purification and characterization of the Escherichia coli K1 neuB gene product N-acetylneuraminic acid synthetase. Glycobiology (1997) 1.05
Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep (1982) 1.05
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control (2001) 1.04
Defective measles virus in human subacute sclerosing panencephalitis brain. Virology (1994) 1.04
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant (1998) 1.03
Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol (2000) 1.03
Selection designs for pilot studies based on survival. Biometrics (1993) 1.02
Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. J Infect Dis (1983) 1.02
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia (2008) 1.01
Splenectomy effects on chemotherapy in Hodgkin's disease. Arch Intern Med (1973) 1.01
cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol (1989) 1.00
The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology (2000) 1.00
Current status of catheter- and stent-based gene therapy. Cardiovasc Res (2004) 1.00
Multiple pulmonary aspergillomas in acute leukemia. Cancer (1971) 0.98
Local full likelihood estimation for the proportional hazards model. Biometrics (1991) 0.97
Comparison of the diagnostic value of bone marrow biopsy and bone marrow aspiration in neoplastic disease. J Clin Pathol (1974) 0.96
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol (1987) 0.96
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol (1988) 0.95
Radioassay for serum vitamin B12 with the use of saliva as the vitamin B12 binder. J Lab Clin Med (1969) 0.95
A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol (1993) 0.94
NADPH oxidase of neutrophils elevates o,o'-dityrosine cross-links in proteins and urine during inflammation. Arch Biochem Biophys (2001) 0.94
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood (1992) 0.93
Outbreak of Legionnaires' disease at University Hospital, Nottingham. Epidemiology, microbiology and control. Epidemiol Infect (1993) 0.93
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood (1994) 0.92
Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol (1990) 0.92
Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer (1979) 0.92
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant (1997) 0.91
Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer (1976) 0.91
Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer. Obstet Gynecol (1978) 0.90
Exertion-induced rhabdomyolysis with acute renal failure and disseminated intravascular coagulation in sickle cell trait. Am J Med (1977) 0.90
Histopathologic review of lymphoma cases from the Southwest Oncology Group. Cancer (1977) 0.90
Autotransplants in multiple myeloma: what have we learned? Blood (1996) 0.90
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res (2002) 0.90
Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant (1995) 0.89
Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med (1995) 0.89
The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group. Blood (1982) 0.89
HLA-A, B, Cw, DRB1, DQB1 and DPB1 alleles and haplotypes in the genetically homogenous Irish population. Int J Immunogenet (2008) 0.88
Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst (1990) 0.87